Literature DB >> 23615118

Impact of 5-HTTLPR and BDNF polymorphisms on response to sertraline versus transcranial direct current stimulation: implications for the serotonergic system.

A R Brunoni1, A H Kemp, P Shiozawa, Q Cordeiro, L C L Valiengo, A C Goulart, B Coprerski, P A Lotufo, D Brunoni, A B A Perez, F Fregni, I M Benseñor.   

Abstract

Transcranial direct current stimulation (tDCS) has been intensively investigated as a non-pharmacological treatment for major depressive disorder (MDD). While many studies have examined the genetic predictors of antidepressant medications, this issue remains to be investigated for tDCS. In the current study, we evaluated whether the BDNF Val66Met and the 5-HTT (5-HTTLPR) polymorphisms were associated with tDCS antidepressant response. We used data from a factorial trial that evaluated the efficacy of tDCS and sertraline and enrolled 120 moderate-to-severe, antidepressant-free participants. In the present study, we used analyses of variance to evaluate whether the BDNF (Val/Val vs. Met-carries) and 5-HTTLPR alleles (long/long vs short-carriers) were predictors of tDCS (active/sham) and sertraline (sertraline/placebo) response. Analyses were conducted on the polymorphisms separately and also on their interaction. Genotype frequencies were in Hardy-Weinberg equilibrium. BDNF polymorphism was not associated with treatment response. We found that 5-HTTLPR predicted tDCS effects as long/long homozygotes displayed a larger improvement comparing active vs. sham tDCS, while short-allele carriers did not. A dose-response relationship between active-sham differences with the long allele was also suggested. These results strengthen the role of the serotonergic system in the tDCS antidepressant effects and expand previous findings that reported that tDCS mechanisms of action partially involve serotonergic receptors. Therefore, we hypothesize that tDCS is a neuromodulation technique that acts over depression through the modulation of serotonergic system and that tDCS "top-down" antidepressant effects might not be optimal in brain networks with a hyperactive amygdala inducing bottom-up effects, such as occurs in short-carriers.
Copyright © 2013 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Brain-derived neurotrophic factor polymorphism; Major depressive disorder; Serotonin selective reuptake blockers; Serotonin-transporter-linked-polymorphic region; Single-nucleotide polymorphism; Transcranial direct current stimulation

Mesh:

Substances:

Year:  2013        PMID: 23615118     DOI: 10.1016/j.euroneuro.2013.03.009

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  20 in total

1.  Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder.

Authors:  Yoshihiko Matsumoto; Chiara Fabbri; Silvia Pellegrini; Stefano Porcelli; Pierluigi Politi; Silvio Bellino; Caterina Iofrida; Veronica Mariotti; Erika Melissari; Marco Menchetti; Valentina Martinelli; Marco Cappucciati; Paola Bozzatello; Elena Brignolo; Paolo Brambilla; Matteo Balestrieri; Alessandro Serretti
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

Review 2.  Brain-derived neurotrophic factor: its impact upon neuroplasticity and neuroplasticity inducing transcranial brain stimulation protocols.

Authors:  L Chaieb; A Antal; G G Ambrus; W Paulus
Journal:  Neurogenetics       Date:  2014-02-25       Impact factor: 2.660

Review 3.  Epigenetic mechanisms underlying the role of brain-derived neurotrophic factor in depression and response to antidepressants.

Authors:  Florian Duclot; Mohamed Kabbaj
Journal:  J Exp Biol       Date:  2015-01-01       Impact factor: 3.312

4.  Transcranial Direct Current Stimulation Use in the Treatment of Neuropsychiatric Disorders: A Brief Review.

Authors:  Sarah M Szymkowicz; Molly E McLaren; Uma Suryadevara; Adam J Woods
Journal:  Psychiatr Ann       Date:  2016-11-08

5.  Prefrontal transcranial direct current stimulation (tDCS) as treatment for major depression: study design and methodology of a multicenter triple blind randomized placebo controlled trial (DepressionDC).

Authors:  Frank Padberg; Ulrike Kumpf; Ulrich Mansmann; Ulrich Palm; Christian Plewnia; Berthold Langguth; Peter Zwanzger; Andreas Fallgatter; Jana Nolden; Max Burger; Daniel Keeser; Rainer Rupprecht; Peter Falkai; Alkomiet Hasan; Silvia Egert; Malek Bajbouj
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-02-28       Impact factor: 5.270

Review 6.  Potential of Transcranial Direct Current Stimulation in Alzheimer's Disease: Optimizing Trials Toward Clinical Use.

Authors:  Giuseppina Pilloni; Leigh E Charvet; Marom Bikson; Nikhil Palekar; Min-Jeong Kim
Journal:  J Clin Neurol       Date:  2022-07       Impact factor: 2.566

7.  A Meta-analysis of Transcranial Direct Current Stimulation Studies Examining the Reliability of Effects on Language Measures.

Authors:  Amy R Price; Harrison McAdams; Murray Grossman; Roy H Hamilton
Journal:  Brain Stimul       Date:  2015-06-27       Impact factor: 8.955

8.  BDNF plasma levels after antidepressant treatment with sertraline and transcranial direct current stimulation: results from a factorial, randomized, sham-controlled trial.

Authors:  André R Brunoni; Rodrigo Machado-Vieira; Carlos A Zarate; Erica L M Vieira; Marie-Anne Vanderhasselt; Michael A Nitsche; Leandro Valiengo; Isabela M Benseñor; Paulo A Lotufo; Wagner F Gattaz; Antonio L Teixeira
Journal:  Eur Neuropsychopharmacol       Date:  2014-03-27       Impact factor: 4.600

Review 9.  The contribution of interindividual factors to variability of response in transcranial direct current stimulation studies.

Authors:  Lucia M Li; Kazumasa Uehara; Takashi Hanakawa
Journal:  Front Cell Neurosci       Date:  2015-05-12       Impact factor: 5.505

10.  Transcranial magnetic stimulation and transcranial direct current stimulation: treatments for cognitive and neuropsychiatric symptoms in the neurodegenerative dementias?

Authors:  Greg J Elder; John-Paul Taylor
Journal:  Alzheimers Res Ther       Date:  2014-11-10       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.